Which type of antagonist is Zafirlukast?

Zafirlukast functions as a leukotriene receptor antagonist. It specifically inhibits the action of leukotrienes, which are inflammatory mediators produced in response to allergens and play a significant role in the pathophysiology of asthma and allergic rhinitis. By blocking these receptors, Zafirlukast helps to reduce bronchoconstriction, mucus secretion, and inflammation in the airways, offering symptomatic relief for asthma patients.

The action of Zafirlukast is crucial in the management of asthma, particularly for those who experience not only acute symptoms but also chronic inflammation due to leukotriene action. This mechanism is particularly helpful for patients who may not respond adequately to other asthma medications such as beta-agonists or glucocorticoids alone.

In contrast to other options, Zafirlukast does not inhibit glucocorticoid receptors, prostaglandin receptors, or nitric oxide synthase, which serve different roles in inflammation and cellular signaling pathways. Thus, its classification as a leukotriene receptor antagonist is what defines its pharmacological usage in treating respiratory conditions.